Perhaps some disappointment around the EBITDA guidance, but the results commentary did suggest a stronger than expected NPAT in H2 2024 due to cost cutting. I guess the proof will be in the pudding. Initially I was pleased by the ex covid testing revenue growth (even accounting for acquisitions), but looking at the even stronger growth in costs, this put a bit of a dampener on it. As you said, no franking credit on dividend.
- Forums
- ASX - By Stock
- Ann: Half Yearly Report and Accounts
Perhaps some disappointment around the EBITDA guidance, but the...
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SHL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$26.10 |
Change
0.350(1.36%) |
Mkt cap ! $12.53B |
Open | High | Low | Value | Volume |
$25.81 | $26.18 | $25.70 | $23.65M | 907.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 230 | $26.09 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$26.12 | 9452 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 520 | 26.050 |
1 | 2000 | 26.040 |
8 | 38642 | 26.010 |
3 | 807 | 26.000 |
2 | 9940 | 25.990 |
Price($) | Vol. | No. |
---|---|---|
26.180 | 7520 | 7 |
26.200 | 3684 | 3 |
26.220 | 3663 | 1 |
26.240 | 9890 | 1 |
26.250 | 5841 | 2 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
SHL (ASX) Chart |